Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials

BACKGROUND: We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) >18 months. PATIENTS AND METHODS: A retrospective analysis of data from 57...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Genitourin Cancer
Auteurs principaux: Tannir, Nizar M., Figlin, Robert A., Gore, Martin E., Michaelson, M. Dror, Motzer, Robert J., Porta, Camillo, Rini, Brian I., Hoang, Caroline, Lin, Xun, Escudier, Bernard
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736765/
https://ncbi.nlm.nih.gov/pubmed/28711490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.06.005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires